Spyre Therapeutics Inc. Total Liabilities
Spyre Therapeutics Inc. total liabilities. Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has total liabilities worth $71.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Spyre Therapeutics Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Spyre Therapeutics Inc. (2013–2025)
Total liabilities of Spyre Therapeutics Inc. from 2013 to 2025. This chart illustrates how Spyre Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Spyre Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Spyre Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reece Ltd
AU:REH
|
Australia | AU$3.58 Billion |
|
Everbright Securities Co Ltd
SHG:601788
|
China | CN¥275.11 Billion |
|
SRF Limited
NSE:SRF
|
India | Rs89.98 Billion |
|
Grupo Aeroportuario del Sureste S. A. B. de C. V
MX:ASURB
|
Mexico | MX$41.52 Billion |
|
Jackson Financial Inc
NYSE:JXN
|
USA | $318.93 Billion |
|
Henry Schein Inc
NASDAQ:HSIC
|
USA | $6.48 Billion |
|
VeriSilicon Microelectronics Shanghai Co Ltd
SHG:688521
|
China | CN¥2.93 Billion |
|
Glaukos Corp
NYSE:GKOS
|
USA | $222.40 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Spyre Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Spyre Therapeutics Inc. total assets.
Liquidity & Leverage Metrics
Spyre Therapeutics Inc. Total Liabilities Ratios Explained
Spyre Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spyre Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spyre Therapeutics Inc. (2013–2025)
The table below shows the annual total liabilities of Spyre Therapeutics Inc. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $62.55 Million | -31.03% |
| 2024-12-31 | $90.68 Million | -42.55% |
| 2023-12-31 | $157.84 Million | +657.44% |
| 2022-12-31 | $20.84 Million | -19.80% |
| 2021-12-31 | $25.98 Million | +19.27% |
| 2020-12-31 | $21.79 Million | -5.70% |
| 2019-12-31 | $23.10 Million | +124.05% |
| 2018-12-31 | $10.31 Million | +79.63% |
| 2017-12-31 | $5.74 Million | +40.10% |
| 2016-12-31 | $4.10 Million | +60.67% |
| 2015-12-31 | $2.55 Million | +141.02% |
| 2014-12-31 | $1.06 Million | -25.07% |
| 2013-12-31 | $1.41 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more